PJSC Borschahivsky Chemical and Pharmaceutical Plant has won a tender organized by the United Nations Development Program (UNDP) for the supply of drugs under the program of pediatric oncology and oncohematology due to the balanced price offer.
Commercial director of the plant Yevhen Sova told Interfax-Ukraine the production of sterile antibiotics, including the direction of oncohematology, is one of the core business of the plant.
“When forming the price offer, we take into account a number of factors: from the price of substances we buy abroad from the same suppliers with which the major international producers work to the cost of manufacturing the drug, including energy costs,” he said.
He stressed the company had opportunities, in particular due to the modern production process, “to offer a price that was lower than that of other participants.”
Sova noted that the plant can compete on an equal basis, in particular with foreign companies, due to reasonable costs for production of medicines.
“This is also possible due to the strict global requirements the plant follows in accordance with the Good Manufacturing Practice (GMP), energy management standards (ISO 50001) and a number of others,” he said.
